All of these tyrosine kinase inhibitors have shown remarkable response rates and benefits in progression-free survival compared to first-line conventional platinum-based chemotherapy [12–21], and thus they have become the standard treatment for patients with metastatic non-small-cell lung cancer harboring EGFR-activating mutations [22]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.